Skip to main content
Arctic Bioscience logo

Arctic Bioscience — Investor Relations & Filings

Ticker · ABS ISIN · NO0010859580 LEI · 549300Z2HW6I989Q2C78 OL Manufacturing
Open in API
Filings indexed 422 across all filing types
Latest filing 2023-12-15 Report Publication Anno…
Country NO Norway
Listing OL ABS

About Arctic Bioscience

https://arctic-bioscience.com/

Arctic Bioscience is a biotechnology company that develops and commercializes pharmaceutical and nutraceutical products derived from marine membrane lipids. The company utilizes proprietary technology to extract bioactive compounds from herring roe, sourced from sustainable, MSC-certified fisheries. Its nutraceutical product line, marketed under the brand name Romega, consists of high-DHA Omega-3 phospholipid extracts. The pharmaceutical division is focused on developing a novel drug candidate for the treatment of mild-to-moderate psoriasis, aligning with its mission to create therapies for autoimmune disorders. The company's work is supported by extensive research and development to validate the efficacy of its marine-based ingredients.

Recent filings

Filing Released Lang Actions
Financial calendar
Report Publication Announcement Classification · 100% confidence The document is titled 'Financial calendar' and lists key future dates for the company, including the release dates for the 'Half-yearly Report' and the 'Annual Report', as well as the date for the 'Annual General Meeting'. Since this document is a schedule of future events and not the actual report or meeting material itself, it does not fit perfectly into 10-K, IR, AGM-R, or ER. It is a general announcement regarding corporate events and reporting schedules. Given the options, this type of forward-looking schedule announcement is best categorized as a general Regulatory Filing (RNS) or potentially a miscellaneous announcement, as it doesn't directly correspond to the specific content types like Dividends, Director Dealing, or Earnings Releases. It is a notification about future corporate actions/reports.
2023-12-15 English
Arctic Bioscience - More than 75% recruited in the phase IIb HeROPA clinical trial
Regulatory Filings Classification · 95% confidence The document is a short announcement providing an update on the recruitment status of a clinical trial (HeROPA phase IIb) for a drug candidate (HRO350). It mentions specific progress (more than 75% recruited) and references a previous update (Q3 update from November 2nd, 2023). It concludes with contact information and a statement subject to Norwegian Securities Trading Act disclosure requirements. This type of operational/progress update, which is not a full financial report (10-K, IR) or a formal earnings release (ER), fits best under the general 'Regulatory Filings' category (RNS) as a specific regulatory disclosure, or potentially a general 'Investor Presentation' (IP) if it were more strategic, but given its nature as a brief operational update subject to disclosure rules, RNS is the most appropriate general regulatory filing category when a more specific category like 'LTR' (Legal) or 'CAP' (Financing) does not apply. Since it is a specific operational update disclosed to the market, RNS is the best fit as a miscellaneous regulatory announcement.
2023-12-01 English
Arctic Bioscience - Over 75% rekruttert til den kliniske fase IIb HeROPA-studien
Regulatory Filings Classification · 95% confidence The document is a short announcement in Norwegian regarding the recruitment progress (over 75% enrolled) in the Phase IIb HeROPA clinical trial for their drug candidate HRO350. It references a previous update (Q3 update from Nov 2, 2023) and provides an expected timeline for data readout (mid-2024). Crucially, it states, "Denne opplysningen er informasjonspliktig etter verdipapirhandelloven § 5-12" (This information is subject to disclosure under the Securities Trading Act § 5-12), indicating it is a mandatory regulatory disclosure of material, non-public information. Given its nature as a specific, material update that doesn't fit the detailed definitions of 10-K, ER, or IR, and is not a presentation (IP) or a formal transcript (CT), it best fits the general category for regulatory announcements that are not otherwise specified, which is Regulatory Filings (RNS). It is too specific to be a general 'News Release' if RNS is available for mandatory disclosures.
2023-12-01 Norwegian
Arctic Bioscience - Q3 2023 Operational update - More than 50% recruited in the phase IIb HeROPA clinical trial
Earnings Release Classification · 100% confidence The document is titled 'Arctic Bioscience - Q3 2023 Operational update' and provides key financial figures (Revenues, Gross profit, Adj. EBITDA) and operational progress (clinical trial recruitment) specifically for the third quarter (Q3 2023). This structure—a summary of operational and financial performance for a period shorter than a full year, including key figures and management commentary—is characteristic of an Interim/Quarterly Report. It is more detailed than a simple Earnings Release (ER) but is not the comprehensive Annual Report (10-K). Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q3 2023
2023-11-02 English
Arctic Bioscience - 3. kv. 2023 oppdatering - Over 50% rekruttert til den kliniske fase IIb HeROPA-studien
Earnings Release Classification · 100% confidence The document is titled "Arctic Bioscience - 3. kv. 2023 oppdatering" (3rd quarter 2023 update) and contains key financial highlights (revenues, gross profit, adjusted EBITDA) for the third quarter and year-to-date, along with operational updates on clinical trials (HeROPA study) and business outlook. This structure—providing summarized financial figures and operational progress for a specific interim period (Q3)—is characteristic of an Earnings Release (ER) or an Interim/Quarterly Report (IR). Since it presents the key highlights and financial numbers immediately, it aligns best with an Earnings Release (ER), which is the initial announcement of periodical financial results. It is not a full Annual Report (10-K) or a comprehensive Interim Report (IR) which usually contains full statements, but rather the summary announcement. The final sentence mentions this information is subject to disclosure requirements under securities law, confirming its regulatory nature as a periodic financial update. Q3 2023
2023-11-02 Norwegian
Arctic Bioscience - HeROPA study recruitment progressing well and strong nutra revenue growth
Investor Presentation Classification · 98% confidence The document is explicitly titled 'Presentation of financial results First half year 2023' and contains an 'Agenda' listing sections like 'Intro and H1-2023 operational highlights', 'H1-2023 consolidated Group financial review', and detailed financial tables for H1-2023. This structure, combined with the presentation format (slides, bullet points, graphics), strongly indicates it is an Investor Presentation (IP) summarizing interim financial results, rather than the full, formal Interim/Quarterly Report (IR) itself. It is a presentation designed for investors to digest the period's performance.
2023-08-29 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.